GlassScriptPhysician profile
Jill Katherine Simon
NPI 1124463336
$2,523.62
in general payments reported to CMS, 2019-2025
29 companies · $633 in 2025
The $633 reported for 2025 was more than what 85% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $239 · 2020: $142 · 2021: $211 · 2022: $436 · 2023: $479 · 2024: $383 · 2025: $633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,401 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,401.29 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $392.43 | 2019-2024 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $248.19 | 2022-2025 | |
| Biogen, INC. | $186.38 | 2024-2025 | Zurzuvae |
| Evofem Biosciences, INC. | $185.90 | 2022-2025 | Phexxi, Solosec, Phexx |
| Abbvie INC. | $169.64 | 2019-2023 | Vraylar, Orilissa |
| Pfizer INC. | $168.54 | 2020-2025 | |
| Avion Pharmaceuticals | $162.09 | 2019-2023 | Balcoltra |
| Bayer Healthcare Pharmaceuticals INC. | $158.03 | 2019-2025 | |
| Hologic Sales and Service, LLC | $106.85 | 2019-2025 | Myosure Tissue Removal Device |
| Therapeuticsmd, INC. | $97.79 | 2019-2022 | |
| Coopersurgical, INC. | $92.51 | 2022-2025 | Endosee, Sos |
| Millicent US INC | $78.17 | 2025 | Intrarosa, Femlyv, Femring |
| Sumitomo Pharma America, INC. | $58.87 | 2023 | Myfembree |
| Exeltis, USA INC. | $57.40 | 2019-2025 | Slynd |
| Innovation Technologies INC | $43.23 | 2024 | Irrisept |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $42.79 | 2023-2024 | Accrufer |
| Aspira Women'S Health INC | $42.23 | 2022 | |
| Agile Therapeutics, INC. | $41.03 | 2021-2022 | |
| Lupin INC. | $28.84 | 2019-2020 | |
| Davol INC. | $28.30 | 2025 | Arista |
| Amag Pharmaceuticals, INC. | $23.43 | 2019-2020 | |
| Pacira Pharmaceuticals Incorporated | $18.05 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.12 | 2021 | |
| Mylan Pharmaceuticals INC. | $14.95 | 2022 | |
| Kci USA, INC. | $13.71 | 2022 | |
| Cequr Corporation | $12.38 | 2025 | Cequr Simplicity |
| Organon LLC | $12.22 | 2024 | |
| Minerva Surgical, INC | $11.92 | 2019 | |
| Merck Sharp & Dohme LLC | $11.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Simon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.